GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Wuhan YZY Biopharma Co Ltd (HKSE:02496) » Definitions » Days Sales Outstanding

Wuhan YZY Biopharma Co (HKSE:02496) Days Sales Outstanding : 86.51 (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Wuhan YZY Biopharma Co Days Sales Outstanding?

Wuhan YZY Biopharma Co's average Accounts Receivable for the six months ended in Dec. 2024 was HK$54.6 Mil. Wuhan YZY Biopharma Co's Revenue for the six months ended in Dec. 2024 was HK$115.1 Mil. Hence, Wuhan YZY Biopharma Co's Days Sales Outstanding for the six months ended in Dec. 2024 was 86.51.

The historical rank and industry rank for Wuhan YZY Biopharma Co's Days Sales Outstanding or its related term are showing as below:

HKSE:02496' s Days Sales Outstanding Range Over the Past 10 Years
Min: 173.03   Med: 173.03   Max: 173.03
Current: 173.03

During the past 4 years, Wuhan YZY Biopharma Co's highest Days Sales Outstanding was 173.03. The lowest was 173.03. And the median was 173.03.

HKSE:02496's Days Sales Outstanding is ranked worse than
85.07% of 844 companies
in the Biotechnology industry
Industry Median: 72.28 vs HKSE:02496: 173.03

Wuhan YZY Biopharma Co's Days Sales Outstanding increased from Dec. 2023 (0.00) to Dec. 2024 (86.51).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.

Wuhan YZY Biopharma Co Days Sales Outstanding Historical Data

The historical data trend for Wuhan YZY Biopharma Co's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan YZY Biopharma Co Days Sales Outstanding Chart

Wuhan YZY Biopharma Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Days Sales Outstanding
- - - 173.03

Wuhan YZY Biopharma Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24
Days Sales Outstanding Get a 7-Day Free Trial - - - - 86.51

Competitive Comparison of Wuhan YZY Biopharma Co's Days Sales Outstanding

For the Biotechnology subindustry, Wuhan YZY Biopharma Co's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Wuhan YZY Biopharma Co's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Wuhan YZY Biopharma Co's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Wuhan YZY Biopharma Co's Days Sales Outstanding falls into.


;
;

Wuhan YZY Biopharma Co Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Wuhan YZY Biopharma Co's Days Sales Outstanding for the fiscal year that ended in Dec. 2024 is calculated as

Days Sales Outstanding (A: Dec. 2024 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2023 ) + Accounts Receivable (A: Dec. 2024 )) / count ) / Revenue (A: Dec. 2024 )*Days in Period
=( (0 + 54.567) / 1 ) / 115.109*365
=54.567 / 115.109*365
=173.03

Wuhan YZY Biopharma Co's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

Days Sales Outstanding (Q: Dec. 2024 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Jun. 2024 ) + Accounts Receivable (A: Dec. 2024 )) / count ) / Revenue (A: Dec. 2024 )*Days in Period
=( (0 + 54.567) / 1 ) / 115.109*365 / 2
=54.567 / 115.109*365 / 2
=86.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wuhan YZY Biopharma Co  (HKSE:02496) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Wuhan YZY Biopharma Co Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Wuhan YZY Biopharma Co's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Wuhan YZY Biopharma Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Wuhan YZY Biopharma Co Ltd (HKSE:02496) » Definitions » Days Sales Outstanding
Comparable Companies
HKSE:02511 HKSE:06622 HKSE:01244 HKSE:06998 HKSE:02898 HKSE:02126 HKSE:02185 HKSE:06628 HKSE:09939 HKSE:00690 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
No. 666 Gaoxin Road, East Lake High Tech, Development Zone, Hubei Province, Wuhan, CHN
Website
https://en.yzybio.com
Wuhan YZY Biopharma Co Ltd is a biotechnology company specifically involved in developing bispecific antibody-based therapies to treat cancer or cancer-associated complications, cancer and age-related ophthalmologic diseases to address medical demands in oncology and aging-related ophthalmologic disease areas, The Company has been operating in one reportable segment, being the discovering, developing and commercializing a new class of medicines in respect to anti-tumor bispecific antibody. It generates the majority of its revenue from PRC.
Executives
Wen Zhicheng 2201 Interest of corporation controlled by you
Guo Hong Wei
Dragon Merit Holdings Limited 2201 Interest of corporation controlled by you
Shi Yao Ji Tuan En Bi Pu Yao Ye You Xian Gong Si 2101 Beneficial owner
Cspc Pharmaceutical Group Limited 2201 Interest of corporation controlled by you
Robust Sun Holdings Limited 2201 Interest of corporation controlled by you
Wang Hongjie 2201 Interest of corporation controlled by you
He Bei Yi Er Qi Ye Guan Li Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Mei Shan Bao Shui Gang Qu Guang Rui Hong Xiang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Guo Xin Si Chuang Tou Zi Ji Jin Guan Li Bei Jing You Xian Gong Si 2201 Interest of corporation controlled by you
Nan Jing Cai Zhi Er Hao Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Cdh 2018 Vgc Investment Fund, L.p. 2201 Interest of corporation controlled by you
Nan Ning Hui You Xing Yao Gu Quan Tou Zi Ji Jin He Huo Qi Ye You Xian He Huo
Nan Ning Yao You Shang Wu Zi Xun He Huo Qi Ye You Xian He Huo
Wen Zhi Cheng

Wuhan YZY Biopharma Co Headlines

No Headlines